Dr. Reddy's reported a weak set of operating numbers. Consolidated revenue of `38,435 mn in Q1FY20, growth of 3% YoY and a decline of 4% QoQ. During the quarter, the company received an amount of `3457 mn (Other income) from Celgene as a settlement agreement related to Revlimid that elevated EBITDA and Net profit. Adjusted EBITDA grew by only 10% YoY to `8,789 during the quarter. Whilst EBITDA margin came in at 20%, decline of 98bps YoY. Gross profit margin for the quarter was...